๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Akashi
Clinical trial register · Japan

Clinical Trials in Akashi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Fukuoka 550 Nagoya 510 Sapporo 402 Tokyo 363 Osaka 345
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC8 Eli Lilly and Company6 Daiichi Sankyo6 NRG Oncology3 Takeda2
Site location
Fukuoka550 Nagoya510 Sapporo402 Tokyo363 Osaka345
All 929 locations
Target enrolment
to

Trials with a site in Akashi

49 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
DrugsRina-S·Bevacizumab
Genmab
Phase 3
544
Sapporo, Akashi, Tsu, Takatsuki, Hidaka, Kashiwa, Kawasaki, Kurume
2026-04-03
Recruiting
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
NCT07410117Cancer-Associated Thrombosis (CAT)
DrugCenvacibart
Regeneron Pharmaceuticals
Phase 3
1,120
Akashi, Kita-gun, Isehara-Shi, Chuo, Kitaadachigun, Ube, Niigata
2026-03-09
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
DrugsSacituzumab tirumotecan·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
900
Nagoya, Kurume, ลŒta, Sapporo, Akashi, Shiwa-gun, Hidaka, Sunto-gun,
2026-02-16
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsSacituzumab tirumotecan·Paclitaxel·Bevacizumab·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,023
Nagoya, Tลon, Kurume, ลŒta, Sapporo, Akashi, Shiwa-gun, Yokohama
2026-01-19
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Nagoya, Kurume-Shi, Hiroshima, Sapporo, Fukuoka, Akashi, Kobe, Yokohama
2025-12-22
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
DrugsR-mini-CHOP·Surovatamig
AstraZeneca
Phase 3
420
Akashi, Bunkyล City, Himeji-shi, Kลtoku, Kumamoto, Matsumoto-shi, Matsuyama, Meguro-ku
2025-11-11
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Akashi, Chลซลku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kลtoku, Nagoya
2025-10-22
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
DrugsPF-08046054·Docetaxel
Pfizer
Phase 3
680
Kurume, Kure, Akashi, Kochi, Tsu, Sendai, ลŒmura, Beppu-shi
2025-09-29
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Nagoya, Matsuyama, Tลon, Kurume, ลŒta, Sapporo, Akashi, Shiwa-gun
2025-05-22
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Nagoya, Toyoake-shi, Kashiwa-shi, Matsuyama, Sapporo, Akashi, Kanazawa, Yokohama
2025-05-06
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Akashi, Bunkyล City, Fukuoka, Hamamatsu, Iwakuni-shi, Izumi-shi, Kashihara-shi, Kobe
2025-04-10
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Akashi, Chลซลku, Fukushima, Hidaka-Shi, Kลtoku, Kurume-shi, Nagoya, Niigata
2025-03-19
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014
DrugsOlaparib·Bevacizumab
NRG Oncology
Phase 3
880
Sendai, Tลon, Kure, Sapporo, Akashi, Shiwa-gun, Kagoshima, Gunma
2025-03-12
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin
BioNTech SE
Phase 2/3
1,580
Ageo, Akashi, Aomori, Bunkyล City, Chลซลku, Funabashi, Himeji, Hiroshima
2025-01-07
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugR-DXd
Daiichi Sankyo
Phase 2
335
Akashi, Chลซลku, Fukuoka, Hidaka, Kashiwa, Kลtoku, Nagoya, Osaka
2025-01-06
Active, closed
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsIBI343·Irinotecan·Paclitaxel
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Kashiwa-shi, Matsuyama, Gifu, Ota-Shi, Kure, Sapporo, Fukuoka, Akashi
2024-06-30
Active, closed
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
NCT06390995Ovarian Cancer, Solid Tumors
Takeda
Phase 1/2
28
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Akashi, Shiwa-gun, Sendai
2024-05-20
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata
2023-12-06
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926Breast Cancer
DrugOvarian Function Suppression
NRG Oncology
Phase 3
3,960
Tลon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2023-10-18
Active, closed
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
398
Kurume, Akashi, Hirakata, Kashiwa, Nagoya, ลŒsaka-sayama, Sapporo, Sendai
2023-06-01
Recruiting
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
NCT05539196Movement Disorders, Neurology, Parkinsons Disease
InSightec
Observational
60
Akashi
2023-01-23
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
DrugAbelacimab
Anthos Therapeutics, Inc.
Phase 3
2,500
Akashi, Chikushino-shi, Chลซลku, Funabashi-Shi, Hamada-shi, Hamamatsu, Himeji-Shi, Imabari
2022-12-27
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsRina-S·Bevacizumab·Carboplatin·Pembrolizumab
Genmab
Phase 1/2
884
Fukushima, ลŒta, Sapporo, Akashi, Hidaka, Nagaizumi-chล, Koto, Shinjuku-ku
2022-12-07
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Akashi, Fukuoka, Hidaka, Hirakata, Iwakuni, Izumi, Kanazawa, Kลtoku
2022-07-08
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Sapporo, Akashi, Kobe
2021-10-04
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887Stage I Breast Cancer
NRG Oncology
Phase 3
1,670
Tลon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2021-06-23
Active, closed
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
NCT04721977Breast Cancer
DrugsTucatinib·Herceptin·Xeloda·Trastuzumab
Pfizer
Phase 2
66
Nagoya, Kashiwa, Matsuyama, Sapporo, Akashi, Nishinomiya, Tsukuba, Yokohama
2021-04-08
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Kashiwa, Tokyo, Matsuyama, Sapporo, Akashi, Chiba, Ariake, Sendai
2021-02-02
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
DrugsKeytruda·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
990
Nagoya, Kashiwa, Matsuyama, Tลon, Kurume, ลŒta, Sapporo, Akashi
2021-01-10
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Docetaxel
Daiichi Sankyo
Phase 3
605
Akashi, Chลซลku, Fukuoka, Hidaka, Hirakata, Kanazawa, Kashiwa, Kลtoku
2020-12-21
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Akashi, Chลซลku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kลtoku
2020-12-04
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Nagoya, Toon-shi, Fukushima, Akashi, Nishinomiya-Shi, Sagamihara, Sendai, Nagasaki
2020-12-02
Recruiting
ONO-4538 Phase II Rollover Study (ONO-4538-98)
NCT04566380Pan-tumor
DrugsTemozolomide·Serplulimab·Nivolumab·Capecitabine
Ono Pharmaceutical Co., Ltd.
Phase 2
59
Kashiwa, Matsuyama, Kurume, Sapporo, Akashi, Yokohama, Yufu, Suita
2020-09-10
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511Alzheimer Disease
DrugDonanemab
Eli Lilly and Company
Phase 3
1,736
Nagoya, ลŒbu, Inage, Akashi, Himeji, Kobe, Inashiki, Toride
2020-06-19
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Akashi, Chuo-ku
2019-12-10
Active, closed
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
NCT04078295Solid Neoplasms
DrugsE7389-LF·Nivolumab
Eisai Co., Ltd.
Phase 1/2
125
Nagoya, Kashiwa, Matsuya, Kurume, Akashi, Yokohama, Sendai, Chuo Ku
2019-09-05
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Akashi, Kawasaki, Kamigyล-ku
2019-07-11
Active, closed
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
NCT05696548Anaplastic Thyroid Cancer
DrugsLenvatinib·Nivolumab
National Cancer Center Hospital East
Phase 2
51
Nagoya, Kashiwa, Hokkaido, Akashi, Kobe, Yokohama, Sendai, Osaka
2019-07-02
Active, closed
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
NCT03807778Non-Small Cell Lung Cancer
DrugMobocertinib
Takeda
Phase 1
53
Nagoya, Toyoake, Kashiwa, Kurume, Sapporo, Akashi, Kanazawa, Yokohama
2019-02-04
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
Nagoya, Kashiwa, Akashi, Kita-gun, Minato, Chiba, Fukuoka, Hiroshima
2018-12-17
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Fukuoka, Akashi, Kawasaki, Yokohama, Suita, Utsunomiya, Chiba, Kashiwa
2018-11-28
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
3,500
Nagoya, Kashiwa, Matsuyama, Tลon, Kurume, Sapporo, Akashi, Himeji
2018-08-21
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
DrugsRucaparib·Opdivo·Nivolumab
pharmaand GmbH
Phase 3
1,097
Tsukuba, Kashiwa, Kurume, Yokohama, Maebashi, Ota-shi, Naka, Akashi
2018-05-14
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
DrugsPemetrexed·Keytruda·Gemcitabine·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
797
Nagoya, Kashiwa, Kitakyushu, Akashi, Kawasaki, Yokohama, Yufu, Fukushima
2018-04-24
Active, closed
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
857
Nagoya, Kashiwa, Sapporo, Akashi, Kanazawa, Osaka Sayama-shi, Nagaizumi-cho,Sunto-gun, Chuo-ku
2017-05-02
Active, closed
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933ALK Positive Malignancies
DrugCeritinib
Novartis Pharmaceuticals
Phase 4
233
Nagoya, Fukuoka, Akashi, Koto Ku
2015-12-11
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
DrugsVinorelbine·Tecentriq·Atezolizumab·Pemetrexed
Hoffmann-La Roche
Phase 3
1,280
Aichi, Akashi, Bunkyล City, Chลซล, Fukuoka, Hiroshima, Kitaadachi-gun, Kitakyushu-shi
2015-10-31
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
DrugsGefitinib·Erlotinib·Ramucirumab·Osimertinib
Eli Lilly and Company
Phase 3
545
Nagoya, Kashiwa, Tลon, Kurume, Asahikawa, Akashi, Amagashiki, Himeji
2015-05-06
Active, closed
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
NCT01872975Stage IB Breast Cancer, Stage II Breast Cancer
NSABP Foundation Inc
Not applicable
1,636
Sendai, Sapporo, Akashi, Morioka, Gunma, Niigata, Matsuyama, Saitama
2013-08
Rows per page Showing 1–49 of 49
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-japan/city/akashi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 49 of those studies with a site in Akashi.

How many clinical trials are recruiting in Akashi?

21 of the 49 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 0 have not yet opened recruitment, 28 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Akashi), 49 studies
PhaseStudiesRecruitingShare
Phase 3321665.3%
Phase 1/25110.2%
Phase 25110.2%
Phase 1204.1%
Phase 2/3224.1%
Not applicable102%
Observational112%
Phase 4102%

Most active sponsors

Lead sponsors with the most studies (Akashi)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC84
Daiichi Sankyo61
Eli Lilly and Company61
NRG Oncology33
AstraZeneca22
Genmab22
Pfizer21
Takeda20
Anthos Therapeutics, Inc.11
ArriVent BioPharma, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.